4.6 Article

Vascular transplantation with dual-biofunctional ePTFE vascular grafts in a porcine model

Journal

JOURNAL OF MATERIALS CHEMISTRY B
Volume 9, Issue 36, Pages 7409-7422

Publisher

ROYAL SOC CHEMISTRY
DOI: 10.1039/d1tb01398j

Keywords

-

Funding

  1. National Natural Science Foundation of China [32071359, 31771058, 11421202, 11827803, 61227902, 11120101001]
  2. National Key Technology RD Program [2016YFC1100704, 2016YFC1101101]
  3. International Joint Research Center of Aerospace Biotechnology and Medical Engineering from Ministry of Science and Technology of China
  4. 111 Project [B13003]
  5. Research Fund for the Doctoral Program of Higher Education of China [20131102130004]
  6. Fundamental Research Funds for the Central Universities

Ask authors/readers for more resources

Cardiovascular disease is a serious global health issue, and the need for improved long-term patency rate in ePTFE vascular grafts for CVD treatment is crucial. Through utilizing polydopamine, bivalirudin, and peptides from extracellular matrix proteins for surface modification, researchers successfully achieved satisfactory patency rate and higher endothelial cell coverage ratio in a porcine carotid artery replacement model.
Cardiovascular disease (CVD) poses serious health concerns worldwide. The lack of transplantable vascular grafts is an unmet clinical need in the surgical treatment of CVD. Although expanded polytetrafluoroethylene (ePTFE) vascular grafts have been used in clinical practice, a low long-term patency rate in small-diameter transplantation application is still the biggest challenge. Thus, surface modification of ePTFE is sought after. In this study, polydopamine (PDA) was used to improve the hydrophilia and provide immobilization sites in ePTFE. Bivalirudin (BVLD), a direct thrombin inhibitor, was used to enhance the anti-thrombotic activity of ePTFE. The peptides derived from extracellular matrix proteins were used to elevate the bioactivity of ePTFE. The morphology, chemical composition, peptide modified strength, wettability, and hemocompatibility of modified ePTFE vascular grafts were investigated. Then, an endothelial cell proliferation assay was used to evaluate the best co-modification strategy of the ePTFE vascular graft in vitro. Since a large animal could relatively better mimic human physiology, we chose a porcine carotid artery replacement model in the current study. The results showed that the BVLD/REDV co-modified ePTFE vascular grafts had a satisfactory patency rate (66.7%) and a higher endothelial cell coverage ratio (70%) at 12 weeks after implantation. This may offer an opportunity to produce a multi-biofunctional ePTFE vascular graft, thereby yielding a potent product to meet the clinical needs.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available